|Articles|July 24, 2019

Orphazyme Extends Use of Montrium‘s Connect Platform

Montrium has announced that Orphazyme, after determining a cloud-based system would bring unique benefits, has chosen to extend Montrium’s eTMF Connect and RegDocs Connect solutions with Quality Connect.

For details, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

© putilov_denis - © putilov_denis - stock.adobe.com

From Participation to Understanding: Reframing Engagement in Clinical Trials

September 9th 2026

Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable

ByOtis Johnson, PhD, MPA,Joseph Geraci, PhD,Andy Studna, Senior Editor

September 9th 2026

ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis

ByAndy Studna, Senior Editor

September 9th 2026

Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run

ByPatrick Mizer,Andy Studna, Senior Editor

September 8th 2026

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

ByAbigail Dirks, MS,Sylviane de Viron,Andy Studna, Senior Editor

September 8th 2026

Trending on Applied Clinical Trials Online

ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD

Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable

ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis